There are currently 103 active clinical trials seeking participants for Endometrial Cancer research studies. The states with the highest number of trials for Endometrial Cancer participants are Texas, New York, California and Ohio.
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
NCT05056077
Recruiting
This clinical trial studies the effect of four different intervention components "tools" on body weight, nutrition, and physical activity in cancer survivors. Studies indicate that people with a history of cancer whose nutrition and physical activity habits are consistent with the American Cancer Society's Nutrition and Physical Activity Guidelines may have longer disease-free survival. The four different intervention components may help patients with a history of cancer adopt recommended health... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of California San Francisco, San Francisco, California
Conditions: Bladder Cancer, Breast Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer, Rectal Cancer, Prostate Cancer, Renal Cell Carcinoma, Kidney Cancer
Register for Updates
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
NCT05683418
Recruiting
The goal of this clinical trial is to evaluate the safety of TOS-358 in adults with select solid tumors who meet study enrollment criteria. The main questions it aims to answer are: 1. what is the maximum tolerated dose and recommended dose for phase 2? 2. how safe and tolerable is TOS-358 at different dose levels when taken orally once or twice per day?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California +17 locations
Conditions: Squamous Cell Carcinoma of Head and Neck, Endometrial Cancer, HR+/HER2-negative Breast Cancer, Bladder Cancer
Register for Updates
A Study of XMT-1660 in Participants With Solid Tumors
NCT05377996
Recruiting
A Study of XMT-1660 in Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange, California +21 locations
Conditions: Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
Register for Updates
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
NCT03832361
Recruiting
The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
07/15/2025
Locations: Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut
Conditions: Endometrial Cancer
Register for Updates
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT04683653
Recruiting
This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in this study. Because this study will shorten the radiation course typically used to treat endometrial cancer, each daily treatment given to women in this study will be slightly higher than normal to en... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Winship Cancer Institute, Emory University, Atlanta, Georgia +4 locations
Conditions: Endometrial Cancer
Register for Updates
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
NCT06925724
Recruiting
The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also look at whether the study drug is safe and causes few or mild side effects in participants.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Endometrial Cancer, Cervical Cancer
Register for Updates
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211
Recruiting
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/10/2025
Locations: Research Site, Los Angeles, California +94 locations
Conditions: Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
Register for Updates
Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence
NCT04930159
Recruiting
The SISTER study is a randomized trial, looking at various modalities of social support for Black patients undergoing treatment for endometrial cancer. There are three study arms: group support, 1:1 peer support, and enhanced usual care. The primary outcome is treatment completion, and the secondary outcome is social isolation.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: University of Alabama, Birmingham, Alabama +10 locations
Conditions: Endometrial Cancer
Register for Updates
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692
Recruiting
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Sharp Memorial Hospital, San Diego, California +26 locations
Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Cutaneous Melanoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, Colorectal Cancer (MSI-H), MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
Register for Updates
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441
Recruiting
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +170 locations
Conditions: Endometrial Cancer
Register for Updates
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194
Recruiting
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Sarah Cannon Research Institute, Denver, Colorado +5 locations
Conditions: Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer
Register for Updates
ASk Questions in GYnecologic Oncology (ASQ-GYO)
NCT06339827
Recruiting
The goal of this clinical trial is to determine the effectiveness of the ASk Questions in GYnecologic Oncology question prompt list (ASQ-GYO QPL) at improving patient self-efficacy, distress, physician trust, and knowledge compared to usual care during new patient gynecologic oncology visits. Also to determine the acceptability of the ASQ-GYO QPL with new gynecologic oncology patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/15/2025
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Gestational Trophoblastic Disease
Register for Updates